D2 lymphadenectomy in reduced-port surgery
- Conditions
- Neoplasms
- Registration Number
- KCT0005241
- Lead Sponsor
- Samsung Medical Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 67
We prospectively enrolled 68 patients with gastric cancer between December 2014 and November 2019. Patients who were planned to undergo surgery (reduced-port [three-port] totally laparoscopic distal gastrectomy [Duet TLDG] D2 LN dissection) at Samsung Medical Center with a histological diagnosis of adenocarcinoma of the stomach; a Eastern Cooperative Oncology Group performance status of 0 or 1; age of between 20 and 80 years; location of the primary tumor in the antrum, angle, or low body; and clinical stage T1-3NxM0, which was determined with preoperative abdominal-pelvic computed tomography, endoscopy, and chest X-ray, were eligible for inclusion in this study.
We excluded patients with metastasis, double primary cancer, those receiving palliative treatment, and those who underwent the resection of another organ during gastrectomy.
Study & Design
- Study Type
- Observational Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method compliance rate : defined as cases in which there was no more than one missing LN station during D2 LN dissection
- Secondary Outcome Measures
Name Time Method the numbers of dissected and retrieved LNs in each station and other short-term surgical outcomes and postoperative course